Interius biotherapeutics. Interius BioTherapeutics, a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, announced a manufacturing partnership with WuXi Advanced Therapies, a global Contract Testing, Development and Manufacturing Organization."The technology that Interius is advancing may dramatically change the way we think about in vivo gene delivery and lead to transformational therapies for patients." About Interius BioTherapeutics Interius BioTherapeutics is a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, creating a ...Sep 2, 2022 · Interius BioTherapeutics is focused on developing a new method to deliver chimeric antigen receptors (CARs) into T cells directly in the human body. Since 2017, the US Food and Drug Administration has approved six CAR-T cell therapies for treating refractory or relapsed lymphomas and leukemias. PHILADELPHIA, Dec. 9, 2021 /PRNewswire/ -- Today, Interius BioTherapeutics, a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, today...PHILADELPHIA, Dec. 9, 2021 /PRNewswire/ -- Today, Interius BioTherapeutics, a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, today...Interius BioTherapeutics is transforming the field of gene therapy with its breakthrough platform for in vivo cell-specific gene delivery. Founded on inventions from the renowned laboratory of Dr. Saar Gill, a physician-scientist at the Center for Cellular Immunotherapies at the University of Pennsylvania, Interius BioTherapeutics is pioneering ...May 9, 2023 by Allen Williams Interius BioTherapeutics, a preclinical stage gene therapy company, has announced a manufacturing partnership with WuXi Advanced Therapies (WuXi ATU) to bring its innovative INT-2104 gene delivery product to the market.HOUSTON, June 6, 2023 /PRNewswire/ -- NKILT Therapeutics, a new biotech company committed to the development of novel natural killer (NK) cell therapies, announced today the appointment to their Scientific Advisory Board (SAB) of Saar Gill, MD, PhD, as Chairman and Maksim Mamonkin, PhD, as scientific advisor.About. Interius BioTherapeutics is a biopharmaceutical company developing a paradigm-shifting platform for in vivo cell-specific gene delivery. Philadelphia, Pennsylvania, United States. 1-10. Series A. Private. interiusbio.com. 6,741. May 18, 2021 · PHILADELPHIA, May 18, 2021 /PRNewswire/ -- Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery,... About. Interius BioTherapeutics is a biopharmaceutical company developing a paradigm-shifting platform for in vivo cell-specific gene delivery. Philadelphia, Pennsylvania, United States. 1-10. Series A. Private. interiusbio.com. 6,741. PHILADELPHIA, May 18, 2021 /PRNewswire/ -- Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery, today announced that it has raised $76 million in an oversubscribed Series A financing.1 day ago · HOUSTON, June 6, 2023 /PRNewswire/ -- NKILT Therapeutics, a new biotech company committed to the development of novel natural killer (NK) cell therapies, announced today the appointment to their Scientific Advisory Board (SAB) of Saar Gill, MD, PhD, as Chairman and Maksim Mamonkin, PhD, as scientific advisor. Interius BioTherapeutics is an early-stage biotechnology company expanding the potential of cell and gene therapy by developing next generation delivery technology based on inventions from the laboratory …"The technology that Interius is advancing may dramatically change the way we think about in vivo gene delivery and lead to transformational therapies for patients." About Interius BioTherapeutics Interius BioTherapeutics is a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, creating a ...May 9, 2023 by Allen Williams Interius BioTherapeutics, a preclinical stage gene therapy company, has announced a manufacturing partnership with WuXi Advanced Therapies (WuXi ATU) to bring its innovative INT-2104 gene delivery product to the market. harden supplysteve huffmanindexventures PHILADELPHIA, May 9, 2023 /PRNewswire/ -- Interius BioTherapeutics, a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, announced a... scodeller construction May 9, 2023 · Right Cell, Right Payload, Right Disease. Interius BioTherapeutics is an early-stage biotechnology company expanding the potential of cell and gene therapy by developing next generation delivery technology based on inventions from the laboratory of Dr. Saar Gill at the University of Pennsylvania. first national bank correctionville iowa We have assembled leading minds from academia and industry to build next-generation cell and gene therapies with better activity, comprehensive engagement of the endogenous immune system and lower toxicity. Leadership Phil Johnson, MD President and Chief Executive Officer Dora Mitchell, PhD Senior Vice President, Operations and Chief of StaffInterius BioTherapeutics is focused on developing a new method to deliver chimeric antigen receptors (CARs) into T cells directly in the human body. Since 2017, the US Food and Drug Administration has approved six CAR-T cell therapies for treating refractory or relapsed lymphomas and leukemias.Oct 5, 2021 · October 5, 2021. The University of Pennsylvania’s (Penn’s) Division of Facilities and Real Estate Services announced today its newest tenant at Pennovation Lab, Interius BioTherapeutics (“Interius”), has signed a 17,743 SF lease advancing cell and gene therapy research at the Pennovation Works innovation ecosystem. commonwealth financial resourcesI Interius BioTherapeutics CEO and key executive team Interius BioTherapeutics's Vice President, Operations is Dora Mitchell. Interius BioTherapeutics's key executives include Dora Mitchell and 5 others. Dora Mitchell Vice President, Operations Bruce Peacock Founder Saar Gill Founder, SAB Chair Lonnie Moulder Chairman Benjamin Lund DirectorPHILADELPHIA, May 18, 2021 /PRNewswire/ -- Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery,... ota insight Interius BioTherapeutics is a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, creating a breakthrough platform with multi-product potential. The company was founded based on inventions from the laboratory of Dr. Saar Gill, ...Oct 21, 2021 · One of several high-value University of Pennsylvania spinouts, Interius Biotherapeutics raised $76 million in a private stock sale in May. Co-founded by biotechnology veteran Bruce Peacock and ... HOUSTON, June 6, 2023 /PRNewswire/ -- NKILT Therapeutics, a new biotech company committed to the development of novel natural killer (NK) cell therapies, announced today the appointment to their Scientific Advisory Board (SAB) of Saar Gill, MD, PhD, as Chairman and Maksim Mamonkin, PhD, as scientific advisor.PHILADELPHIA, May 9, 2023 /PRNewswire/ — Interius BioTherapeutics, a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, announced a manufacturing partnership with WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO).Mar 8, 2023 · (215) 608-9333 Company Interius BioTherapeutics Jim Richardson Current Workplace Jim Richardson has been working as a Senior Director, Analytical Development at Interius BioTherapeutics for 2 years. Interius BioTherapeutics is part of the Healthcare Services industry, and located in Pennsylvania, United States. Interius BioTherapeutics Location Gill: Interius Biotherapeutics: Current holder of stock options in a privately-held company, Research Funding; Novartis: Other: licensed intellectual property, Research Funding; Carisma Therapeutics: Current holder of stock options in a privately-held company, Research Funding.Interius BioTherapeutics Is Seeking a Sr. Scientist, Analytical Development to join us on our incredible journey Can you see yourself as part of a growing team engineering cells inside the human body for the treatment of devastating diseases? That's what Interians are doing, right now. privcap HOUSTON, June 6, 2023 /PRNewswire/ -- NKILT Therapeutics, a new biotech company committed to the development of novel natural killer (NK) cell therapies, announced today the appointment to their...Interius BioTherapeutics is transforming the field of gene therapy with its breakthrough platform for in vivo cell-specific gene delivery. Founded on inventions from the renowned laboratory of Dr. Saar Gill, a physician-scientist at the Center for Cellular Immunotherapies at the University of Pennsylvania, Interius BioTherapeutics is pioneering ... moore strategic ventures "The technology that Interius is advancing may dramatically change the way we think about in vivo gene delivery and lead to transformational therapies for patients." About Interius BioTherapeutics Interius BioTherapeutics is a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, creating a ... Sep 2, 2022 · Interius BioTherapeutics is focused on developing a new method to deliver chimeric antigen receptors (CARs) into T cells directly in the human body. Since 2017, the US Food and Drug Administration has approved six CAR-T cell therapies for treating refractory or relapsed lymphomas and leukemias. PHILADELPHIA, Dec. 9, 2021 /PRNewswire/ -- Today, Interius BioTherapeutics, a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, today announced that the US Patent and Trademark Office (USPTO) has granted U.S. patent number US11191784, titled "The Methods and Composition for Gene Delivery Using an Engineered Viral Particle." tremle PHILADELPHIA, Dec. 9, 2021 /PRNewswire/ -- Today, Interius BioTherapeutics, a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, today announced that the US Patent and Trademark Office (USPTO) has granted U.S. patent number US11191784, titled "The Methods and Composition for Gene Delivery Using an Engineered Viral Particle."Interius BioTherapeutics is an early-stage biotechnology company expanding the potential of cell and gene therapy by developing next generation delivery technology based on inventions from the laboratory of Dr. Saar Gill at the University of Pennsylvania. south dakota soybean processors llc PHILADELPHIA, Dec. 9, 2021 /PRNewswire/ -- Today, Interius BioTherapeutics, a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, today...PHILADELPHIA, May 18, 2021 /PRNewswire/ -- Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery,...Oct 5, 2021 · The University of Pennsylvania’s (Penn’s) Division of Facilities and Real Estate Services announced today its newest tenant at Pennovation Lab, Interius BioTherapeutics (“Interius”), has signed a 17,743 SF lease advancing cell and gene therapy research at the Pennovation Works innovation ecosystem. afinipay May 9, 2023 · Interius BioTherapeutics is a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, creating a breakthrough platform with multi-product potential. Interius BioTherapeutics is an early-stage biotechnology company expanding the potential of cell and gene therapy by developing next generation delivery technology based on inventions from the laboratory of Dr. Saar Gill at the University of Pennsylvania. Interius BioTherapeutics Overview Update this profile Founded 2019 Status Private Employees 52 Latest Deal Type Series A Latest Deal Amount $76M Investors 16 General Information Description Developer of a gene delivery platform designed to treat hematologic malignancies and other cancers. olo com 1 day ago · HOUSTON, June 6, 2023 /PRNewswire/ -- NKILT Therapeutics, a new biotech company committed to the development of novel natural killer (NK) cell therapies, announced today the appointment to their... Interius BioTherapeutics, a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, announced a manufacturing partnership with WuXi Advanced Therapies, a global Contract Testing, Development and Manufacturing Organization. blum health el paso Interius BioTherapeutics is an early-stage biotechnology company expanding the potential of cell and gene therapy by developing next generation delivery technology based on inventions from the laboratory …Sep 2, 2022 · Interius BioTherapeutics is focused on developing a new method to deliver chimeric antigen receptors (CARs) into T cells directly in the human body.. Since 2017, the US Food and Drug Administration has approved six CAR-T cell therapies for treating refractory or relapsed lymphomas and leukemias. Nov 5, 2021 · Gill: Interius Biotherapeutics: Current holder of stock options in a privately-held company, Research Funding; Novartis: Other: licensed intellectual property, Research Funding; Carisma Therapeutics: Current holder of stock options in a privately-held company, Research Funding. h and r accounts Gill: Interius Biotherapeutics: Current holder of stock options in a privately-held company, Research Funding; Novartis: Other: licensed intellectual property, Research Funding; Carisma Therapeutics: Current holder of stock options in a privately-held company, Research Funding.May 9, 2023 · PHILADELPHIA, May 9, 2023 /PRNewswire/ -- Interius BioTherapeutics, a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, announced a manufacturing partnership with WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO). Ensoma and Interius BioTherapeutics: in vivo veritas Two startups are developing tools to do cell and gene engineering directly in the human body Esther Landhuis The cell and gene therapy field... krakvet Sep 2, 2022 · Interius BioTherapeutics is focused on developing a new method to deliver chimeric antigen receptors (CARs) into T cells directly in the human body.. Since 2017, the US Food and Drug Administration has approved six CAR-T cell therapies for treating refractory or relapsed lymphomas and leukemias. May 18, 2021 · PHILADELPHIA, May 18, 2021 – Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery, today announced that it has raised $76 million in an oversubscribed Series A financing. Mar 8, 2023 · (215) 608-9333 Company Interius BioTherapeutics Jim Richardson Current Workplace Jim Richardson has been working as a Senior Director, Analytical Development at Interius BioTherapeutics for 2 years. Interius BioTherapeutics is part of the Healthcare Services industry, and located in Pennsylvania, United States. Interius BioTherapeutics Location bridgewater associates address Interius BioTherapeutics, a preclinical stage gene therapy company, has raised $76 million in Series A financing. Iris Dorbian - 18 May 2021. Share A-A + 100%.VDOMDHTMLtml> Interius BioTherapeutics Raises $76M Series A Financing to Advance Breakthrough Cell and Gene Therapy Platform | Bain Capital Bain Capital, LP is one of the world’s leading multi-asset alternative investment firms.Interius Biotherapeutics 2021 - Present2 years Biotechnology Consultant Caicos Partners 2016 - Present7 years Greater Philadelphia Venture Partner Apple Tree Partners 2019 - 20201 year Greater... workpay If you're a small business in need of assistance, please contact [email protected]
Jan 1, 2019 · Interius BioTherapeutics Overview Update this profile Founded 2019 Status Private Employees 52 Latest Deal Type Series A Latest Deal Amount $76M Investors 16 General Information Description Developer of a gene delivery platform designed to treat hematologic malignancies and other cancers. Interius BioTherapeutics Overview Work Here? Claim your Free Employer Profile Website: interiusbio.com/ Headquarters: Philadelphia, PA Size: Unknown Type: Company - Private Industry: Biotechnology Revenue: Unknown / Non-Applicable Competitors: Unknown What are your colleagues talking about? william henry llc "The technology that Interius is advancing may dramatically change the way we think about in vivo gene delivery and lead to transformational therapies for patients." About Interius BioTherapeutics Interius BioTherapeutics is a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, creating a ...Nov 5, 2021 · Gill: Interius Biotherapeutics: Current holder of stock options in a privately-held company, Research Funding; Novartis: Other: licensed intellectual property, Research Funding; Carisma Therapeutics: Current holder of stock options in a privately-held company, Research Funding. Research Associate at Interius BioTherapeutics . Verified. Julia Nguyen is a Research Associate at Interius BioTherapeutics based in Philadelphia, Pennsylvania. Read More . Contact. Julia Nguyen's Phone Number and Email Last Update. 6/4/2023 5:39 AM. Email. j***@interiusbio.com. Engage via Email.VDOMDHTMLtml> Interius BioTherapeutics Raises $76M Series A Financing to Advance Breakthrough Cell and Gene Therapy Platform | Bain Capital Bain Capital, LP is one of the world’s leading multi-asset alternative investment firms. PHILADELPHIA, May 9, 2023 /PRNewswire/ — Interius BioTherapeutics, a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, announced a manufacturing partnership with WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO). madrona venture group /PRNewswire/ -- Interius BioTherapeutics, a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, announced... Interius BioTherapeutics...May 18, 2021 · PHILADELPHIA, May 18, 2021 /PRNewswire/ -- Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery, today announced that it has raised $76 million in an oversubscribed Series A financing. May 9, 2023 · Interius BioTherapeutics is transforming the field of gene therapy with its breakthrough platform for in vivo cell-specific gene delivery. Founded on inventions from the renowned laboratory of Dr. Saar Gill, a physician-scientist at the Center for Cellular Immunotherapies at the University of Pennsylvania, Interius BioTherapeutics is pioneering ... May 09 2023 - 12:01AM PR Newswire (US) Interius BioTherapeutics Develops Wholly Owned Process for Lentiviral Vector Manufacturing; Leverages WuXi Advanced Therapies' ("WuXi ATU") plasmid and... secondnature.ai May 9, 2023 · May 9, 2023 by Allen Williams Interius BioTherapeutics, a preclinical stage gene therapy company, has announced a manufacturing partnership with WuXi Advanced Therapies (WuXi ATU) to bring its innovative INT-2104 gene delivery product to the market. Sep 2, 2022 · Interius BioTherapeutics is focused on developing a new method to deliver chimeric antigen receptors (CARs) into T cells directly in the human body.. Since 2017, the US Food and Drug Administration has approved six CAR-T cell therapies for treating refractory or relapsed lymphomas and leukemias. May 18, 2021 · By John George – Senior Reporter, Philadelphia Business Journal May 18, 2021 A two-year-old Philadelphia gene therapy company spun out of the University of Pennsylvania has raised $76 million in... electronicformsllc 1 day ago · HOUSTON, June 6, 2023 /PRNewswire/ -- NKILT Therapeutics, a new biotech company committed to the development of novel natural killer (NK) cell therapies, announced today the appointment to their Scientific Advisory Board (SAB) of Saar Gill, MD, PhD, as Chairman and Maksim Mamonkin, PhD, as scientific advisor. PHILADELPHIA, Dec. 9, 2021 /PRNewswire/ -- Today, Interius BioTherapeutics, a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, today...Interius Biotherapeutics 2021 - Present2 years Biotechnology Consultant Caicos Partners 2016 - Present7 years Greater Philadelphia Venture Partner Apple Tree Partners 2019 - 20201 year Greater... aboveboard PHILADELPHIA, May 9, 2023 /PRNewswire/ — Interius BioTherapeutics, a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, announced a manufacturing partnership with WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO).HOUSTON, June 6, 2023 /PRNewswire/ -- NKILT Therapeutics, a new biotech company committed to the development of novel natural killer (NK) cell therapies, announced today the appointment to their ...I Interius BioTherapeutics CEO and key executive team Interius BioTherapeutics's Vice President, Operations is Dora Mitchell. Interius BioTherapeutics's key executives include Dora Mitchell and 5 others. Dora Mitchell Vice President, Operations Bruce Peacock Founder Saar Gill Founder, SAB Chair Lonnie Moulder Chairman Benjamin Lund Director workatoInterius BioTherapeutics is transforming the field of gene therapy with its breakthrough platform for in vivo cell-specific gene delivery. Founded on inventions from the renowned laboratory of Dr. Saar Gill, a physician-scientist at the Center for Cellular Immunotherapies at the University of Pennsylvania, Interius BioTherapeutics is pioneering ...The University of Pennsylvania’s (Penn’s) Division of Facilities and Real Estate Services announced today its newest tenant at Pennovation Lab, Interius BioTherapeutics (“Interius”), has signed a 17,743 SF lease advancing cell and gene therapy research at the Pennovation Works innovation ecosystem.Oversubscribed round co-led by Cormorant Asset Management and Fairmount Funds, supported by a strong syndicate of new and existing investors. PHILADELPHIA, May 18, 2021 /PRNewswire/ -- Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery, today announced that it has raised $76 million in an ... travera Mar 13, 2023 · (215) 608-9333 Company Interius BioTherapeutics Taylor Phillips Current Workplace Taylor Phillips has been working as a Associate Director, Lab Operations at Interius BioTherapeutics for 6 months. Interius BioTherapeutics is part of the Healthcare Services industry, and located in Pennsylvania, United States. Interius BioTherapeutics Location Interius BioTherapeutics is a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, creating a breakthrough platform with multi-product potential. The company was founded based on inventions from the laboratory of Dr. Saar Gill, a leading physician-scientist in the fields of cell and gene therapy at the Center …PHILADELPHIA, May 18, 2021 /PRNewswire/ -- Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery, today announced that it has raised $76 million in an oversubscribed Series A financing.By John George – Senior Reporter, Philadelphia Business Journal May 18, 2021 A two-year-old Philadelphia gene therapy company spun out of the University of Pennsylvania has raised $76 million in... tokmanni HOUSTON, June 6, 2023 /PRNewswire/ -- NKILT Therapeutics, a new biotech company committed to the development of novel natural killer (NK) cell therapies, announced today the appointment to their...Interius Biotherapeutics 2021 - Present2 years Biotechnology Consultant Caicos Partners 2016 - Present7 years Greater Philadelphia Venture Partner Apple Tree Partners 2019 - 20201 year Greater... jeff buie The company's services aspires to transform cell and gene therapy through in-vivo generation of therapeutic immune and blood cells including chimeric antigen receptor T Cells (CAR-T) for cancers, regulatory T Cells (Treg) for autoimmune diseases and CD34+ hematopoietic stem cells (HSC) for blood disorders, enabling physicians to get the efficien...HOUSTON, June 6, 2023 /PRNewswire/ -- NKILT Therapeutics, a new biotech company committed to the development of novel natural killer (NK) cell therapies, announced today the appointment to their...Interius BioTherapeutics is a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, creating a breakthrough platform with multi-product potential. The company was founded based on inventions from the laboratory of Dr. Saar Gill, ...HOUSTON, June 6, 2023 /PRNewswire/ -- NKILT Therapeutics, a new biotech company committed to the development of novel natural killer (NK) cell therapies, announced today the appointment to their... stytch Mar 13, 2023 · (215) 608-9333 Company Interius BioTherapeutics Taylor Phillips Current Workplace Taylor Phillips has been working as a Associate Director, Lab Operations at Interius BioTherapeutics for 6 months. Interius BioTherapeutics is part of the Healthcare Services industry, and located in Pennsylvania, United States. Interius BioTherapeutics Location Interius BioTherapeutics is a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, creating a breakthrough platform with multi-product potential.Dec 9, 2021 · PHILADELPHIA, Dec. 9, 2021 /PRNewswire/ -- Today, Interius BioTherapeutics, a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, today announced that the US Patent and Trademark Office (USPTO) has granted U.S. patent number US11191784, titled "The Methods and Composition for Gene Delivery Using an Engineered Viral Particle." Dec 9, 2021 · Interius BioTherapeutics is a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, creating a breakthrough platform with multi-product potential. omiq Oct 8, 2021 · Interius BioTherapeutics The cell and gene therapy company spun out of the University of Pennsylvania has signed a lease deal to occupy about 17,700 square feet at Pennovation Lab in the Greys... PHILADELPHIA, May 9, 2023 /PRNewswire/ -- Interius BioTherapeutics, a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, announced a manufacturing partnership with WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO).PHILADELPHIA, Dec. 9, 2021 /PRNewswire/ -- Today, Interius BioTherapeutics, a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, today... ac dellovade The company's services aspires to transform cell and gene therapy through in-vivo generation of therapeutic immune and blood cells including chimeric antigen receptor T Cells (CAR-T) for cancers, regulatory T Cells (Treg) for autoimmune diseases and CD34+ hematopoietic stem cells (HSC) for blood disorders, enabling physicians to get the efficien...Interius is an early-stage biotechnology company expanding the potential of cell and gene therapy by developing next-generation delivery technology based on inventions from the laboratory of Dr. Saar Gill at the University of Pennsylvania.Interius BioTherapeutics General Information. Description. Developer of a gene delivery platform designed to treat hematologic malignancies and other cancers. The company's platform develops chimeric antigen receptor T cells directly in vivo that bypasses the need for ex vivo cell manipulations and the potentially toxic pre-conditioning … verdant specialty solutions Oct 8, 2021 · Interius BioTherapeutics The cell and gene therapy company spun out of the University of Pennsylvania has signed a lease deal to occupy about 17,700 square feet at Pennovation Lab in the Greys... Investors 17 Funding Interius BioTherapeutics has raised a total of $81.5M in funding over 2 rounds. Their latest funding was raised on May 18, 2021 from a Series A round. Interius BioTherapeutics is funded by 17 investors. Penn Medicine Co-Investment Program and Agent Capital are the most recent investors. Funding Rounds Number of Funding Rounds 2 carl lindner iii Our Strong Commitment to Supporting what Matters Most to Interians: Five Pillars of Wellness. Interius is assembling the brightest minds from academia and industry to build next-generation genetic therapies. To achieve our mission, we need to think our best, perform our best, be the best.Apr 2, 2020 · Posted on April 2, 2020 Another Philadelphia biopharmaceutical company spun out the University of Pennsylvania and targeting cancer has attracted a multimillion-dollar investment. Interius BioTherapeutics, founded by Dr. Saar Gill, raised $1.58 million from private investors in an equity financing. Read more on the Philadelphia Business Journal BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific ...Interius BioTherapeutics Raises $76M Series A Financing to Advance Breakthrough Cell and Gene Therapy PlatformThe Online Safety Bill offers hope to parents who have become increasingly concerned over social media and its bdp international houston What: Interius BioTherapeutics is a Philadelphia-based preclinical stage biotechnology company initially focused on treating hematologic malignancies by leveraging its novel gene delivery...PHILADELPHIA, May 18, 2021 – Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery, today announced that it has raised $76 million in an oversubscribed Series A financing.About us. Interius is an early-stage biotechnology company expanding the potential of cell and gene therapy by developing next-generation delivery technology based on inventions from the ... Dec 9, 2021 · PHILADELPHIA, Dec. 9, 2021 /PRNewswire/ -- Today, Interius BioTherapeutics, a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, today... alitheon HOUSTON, June 6, 2023 /PRNewswire/ -- NKILT Therapeutics, a new biotech company committed to the development of novel natural killer (NK) cell therapies, announced today the appointment to their...May 18, 2021 · Oversubscribed round co-led by Cormorant Asset Management and Fairmount Funds, supported by a strong syndicate of new and existing investors. PHILADELPHIA, May 18, 2021 /PRNewswire/ -- Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery, today announced that it has raised $76 million in an ... HOUSTON, June 6, 2023 /PRNewswire/ -- NKILT Therapeutics, a new biotech company committed to the development of novel natural killer (NK) cell therapies, announced today the appointment to their Scientific Advisory Board (SAB) of Saar Gill, MD, PhD, as Chairman and Maksim Mamonkin, PhD, as scientific advisor.PHILADELPHIA, May 18, 2021 /PRNewswire/ -- Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery,... webbly PHILADELPHIA, May 18, 2021 – Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery, today announced that it has raised $76 million in an oversubscribed Series A financing.1 day ago · HOUSTON, June 6, 2023 /PRNewswire/ -- NKILT Therapeutics, a new biotech company committed to the development of novel natural killer (NK) cell therapies, announced today the appointment to their Scientific Advisory Board (SAB) of Saar Gill, MD, PhD, as Chairman and Maksim Mamonkin, PhD, as scientific advisor. davis st auto Interius BioTherapeutics is an early-stage biotechnology company expanding the potential of cell and gene therapy by developing next generation delivery technology based on inventions from the laboratory of Dr. Saar Gill at the University of Pennsylvania. molex maumelle ar 1 day ago · HOUSTON, June 6, 2023 /PRNewswire/ -- NKILT Therapeutics, a new biotech company committed to the development of novel natural killer (NK) cell therapies, announced today the appointment to their Scientific Advisory Board (SAB) of Saar Gill, MD, PhD, as Chairman and Maksim Mamonkin, PhD, as scientific advisor. The company's services aspires to transform cell and gene therapy through in-vivo generation of therapeutic immune and blood cells including chimeric antigen receptor T Cells (CAR-T) for cancers, regulatory T Cells (Treg) for autoimmune diseases and CD34+ hematopoietic stem cells (HSC) for blood disorders, enabling physicians to get the efficien... Oct 5, 2021 · October 5, 2021. The University of Pennsylvania’s (Penn’s) Division of Facilities and Real Estate Services announced today its newest tenant at Pennovation Lab, Interius BioTherapeutics (“Interius”), has signed a 17,743 SF lease advancing cell and gene therapy research at the Pennovation Works innovation ecosystem. HOUSTON, June 6, 2023 /PRNewswire/ -- NKILT Therapeutics, a new biotech company committed to the development of novel natural killer (NK) cell therapies, announced today the appointment to their... ralali b2b
Solutions from Interius biotherapeutics, Inc. Yellow Pages directories can mean big success stories for your. interius biotherapeutics White Pages are public records which are documents or pieces of information that are not considered confidential and can be viewed instantly online. me/interius biotherapeutics If you're a small business in need of assistance, please contact [email protected]